Cardlytics Yönetim

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexis DeSieno	Chief Financial Officer	1.3yrs	US$5.35m	0.20% $ 406.1k
Amit Gupta	COO & GM of Bridg	1.8yrs	US$2.66m	0.36% $ 740.9k
Nick Lynton	Chief Legal & Privacy Officer and Secretary	2.3yrs	US$1.06m	0.17% $ 354.6k
Peter Chan	Chief Technology Officer	3.4yrs	Veri yok	Veri yok
Peter Davies	Head of Sales Strategy & Operations	4.3yrs	Veri yok	Veri yok
Carson Napps	Chief People Officer	1.4yrs	Veri yok	Veri yok
Jose Singer	Chief Product Officer	2.5yrs	Veri yok	Veri yok
Evelyne Forester	Chief Business Officer	1.2yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

41yo

Ortalama Yaş

Deneyimli Yönetim: CDLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Hill	Independent Director	1.2yrs	US$132.77k	0.094% $ 194.0k
Liane Hornsey	Independent Director	less than a year	Veri yok	0.020% $ 41.5k
John Klinck	Independent Chairperson of the Board	8.1yrs	US$216.85k	0.14% $ 280.5k
Andre Fernandez	Independent Director	less than a year	Veri yok	Veri yok
Jessica Jensen	Independent Director	4.3yrs	US$205.00k	0.077% $ 160.2k
Srishti Gupta	Director	less than a year	Veri yok	Veri yok
Aimée Lapic	Independent Director	5.6yrs	US$210.00k	0.086% $ 178.1k
Jonathan Francis	Independent Director	less than a year	Veri yok	Veri yok
Alex Mishurov	Independent Director	1.2yrs	Veri yok	0.25% $ 525.0k

1.2yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CDLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Cardlytics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

High number of new directors

Recent updates

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?